Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease
Yue Cao, Christian Hölscher, Meng-Ming Hu, et al.
European Journal of Pharmacology (2018) Vol. 827, pp. 215-226
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease
Thuy Trang Nguyen, Qui Thanh Hoai Ta, Thi Kim Oanh Nguyen, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3165-3165
Open Access | Times Cited: 250
The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
Niklas Reich, Christian Hölscher
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 110
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Dhruv Gupta, et al.
Ageing Research Reviews (2023) Vol. 89, pp. 101979-101979
Open Access | Times Cited: 78
Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects
Bin Tong, Yaoqi Ba, Zhengyang Li, et al.
Neurobiology of Disease (2024) Vol. 196, pp. 106505-106505
Open Access | Times Cited: 16
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Christian Hölscher
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 4, pp. 333-348
Open Access | Times Cited: 135
Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics
Therese S. Salameh, Elizabeth M. Rhea, Konrad Talbot, et al.
Biochemical Pharmacology (2020) Vol. 180, pp. 114187-114187
Open Access | Times Cited: 104
Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Christian Hölscher
British Journal of Pharmacology (2021) Vol. 179, Iss. 4, pp. 695-714
Open Access | Times Cited: 95
Cognitive dysfunction: A growing link between diabetes and Alzheimer's disease
Kavya Jash, Piyush Gondaliya, Prathibha Kirave, et al.
Drug Development Research (2019) Vol. 81, Iss. 2, pp. 144-164
Closed Access | Times Cited: 92
GLP-1’s role in neuroprotection: a systematic review
Damla Erbil, Candan Yasemin Eren, Çağrı Demirel, et al.
Brain Injury (2019) Vol. 33, Iss. 6, pp. 734-819
Closed Access | Times Cited: 86
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Paul Edison
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 217-229
Open Access | Times Cited: 63
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Sonalika Bhalla, Sidharth Mehan, Andleeb Khan, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 142, pp. 104896-104896
Closed Access | Times Cited: 61
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Haiyang Du, Xiaoyu Meng, Yao Yu, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 48
Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
Yixuan Wang, Hao Hu, Xinyu Liu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 35
Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges
Jacky Tran, Sneh Parekh, Julia Rockcole, et al.
Life Sciences (2024) Vol. 355, pp. 123001-123001
Closed Access | Times Cited: 8
GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models
Zhenqiang Zhang, Christian Hölscher
Peptides (2019) Vol. 125, pp. 170184-170184
Closed Access | Times Cited: 71
Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology
Martina Holubová, Lucie Hrubá, Andrea Popelová, et al.
Neuropharmacology (2018) Vol. 144, pp. 377-387
Closed Access | Times Cited: 66
Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases
André F. Batista, Victor Bodart‐Santos, Fernanda G. De Felice, et al.
CNS Drugs (2018) Vol. 33, Iss. 3, pp. 209-223
Closed Access | Times Cited: 60
Suvorexant ameliorates cognitive impairments and pathology in APP/PS1 transgenic mice
Fang Zhou, Xudong Yan, Chun Wang, et al.
Neurobiology of Aging (2020) Vol. 91, pp. 66-75
Closed Access | Times Cited: 50
Targeting Insulin Resistance to Treat Cognitive Dysfunction
Anit Tyagi, Subbiah Pugazhenthi
Molecular Neurobiology (2021) Vol. 58, Iss. 6, pp. 2672-2691
Open Access | Times Cited: 42
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Federica Ferrari, Antonio Moretti, R. F. Villa
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108277-108277
Closed Access | Times Cited: 32
Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease
Geisa Nogueira Salles, Michele Longoni Calió, Christian Hölscher, et al.
Neuropharmacology (2019) Vol. 162, pp. 107813-107813
Closed Access | Times Cited: 49
Curcumin Promotes Proliferation of Adult Neural Stem Cells and the Birth of Neurons in Alzheimer's Disease Mice via Notch Signaling Pathway
Jun Li, Yazhou Han, Mingduo Li, et al.
Cellular Reprogramming (2019) Vol. 21, Iss. 3, pp. 152-161
Open Access | Times Cited: 48
The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD
Li Cheng, Weizhen Liu, Xiaohui Li, et al.
Brain and Behavior (2020) Vol. 10, Iss. 3
Open Access | Times Cited: 47
The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer’s Disease
Mark Maskery, Elizabeth Mary Goulding, Simon Gengler, et al.
American Journal of Alzheimer s Disease & Other Dementias® (2020) Vol. 35
Open Access | Times Cited: 43
A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer’s Disease
Jessica Lynn, Mingi Park, Christiana Ogunwale, et al.
Journal of Alzheimer s Disease (2021) Vol. 85, Iss. 2, pp. 485-501
Closed Access | Times Cited: 33
Page 1 - Next Page

Scroll to top